Medicinal chemistry–driven discovery of novel SGLT2 inhibitors using integratedin silicoapproaches
نویسندگان
doi
10.48309/jmpcr.2026.569462.1965چکیده
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that is associated with severe cardiovascular and renal complications. Sodium–glucose co-transporter 2 (SGLT2) inhibitors have emerged as an effective therapeutic class for managing hyperglycemia and its associated comorbidities. In this study, an integrated ligand- and structure-based virtual screening approach was employed to identify novel SGLT2 inhibitors with improved pharmacological profiles. Using the high-resolution crystal structure of human SGLT2 (PDB ID: 7VSI) complexed with empagliflozin, over 1.5 million compounds from the COCONUT, PubChem, and ChEMBL databases were screened. Molecular docking and refinement identified four lead compounds exhibiting binding energies ranging from –11.7 to –13.4 kcal/mol, comparable to or better than that of empagliflozin. Molecular dynamics simulations over 100 ns demonstrated stable protein–ligand complexes, with root mean square deviation values below 0.35 nm. Among the screened compounds, 137160716 displayed strong and persistent interactions within the SGLT2 binding pocket. ADMET and drug-likeness analyses further supported the favorable pharmacokinetic properties of compounds 137160716 and 90067346. Overall, this study highlights the potential of combining natural-product-based databases with advanced in silico techniques to identify promising next-generation SGLT2 inhibitors for T2DM management .